Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1-negative or weakly positive advanced non-small-cell lung cancer after disease progression on platinum-based therapy. (EMERALD study) (WJOG10317L)

Trial Profile

Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1-negative or weakly positive advanced non-small-cell lung cancer after disease progression on platinum-based therapy. (EMERALD study) (WJOG10317L)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Docetaxel (Primary) ; Ramucirumab (Primary) ; Atezolizumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms EMERALD study; RAM+DOC vs Atezo
  • Most Recent Events

    • 27 Mar 2018 Planned initiation date changed from 1 May 2018 to 27 Mar 2018.
    • 07 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top